140 related articles for article (PubMed ID: 18852277)
21. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
Nuermberger EL; Yoshimatsu T; Tyagi S; O'Brien RJ; Vernon AN; Chaisson RE; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2004 Feb; 169(3):421-6. PubMed ID: 14578218
[TBL] [Abstract][Full Text] [Related]
22. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
Nuermberger EL; Yoshimatsu T; Tyagi S; Williams K; Rosenthal I; O'Brien RJ; Vernon AA; Chaisson RE; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2004 Nov; 170(10):1131-4. PubMed ID: 15306535
[TBL] [Abstract][Full Text] [Related]
23. In situ TLR2 and TLR4 expression in a murine model of mycetoma caused by Nocardia brasiliensis.
Millán-Chiu BE; Hernández-Hernández F; Pérez-Torres A; Méndez-Tovar LJ; López-Martínez R
FEMS Immunol Med Microbiol; 2011 Apr; 61(3):278-87. PubMed ID: 21205004
[TBL] [Abstract][Full Text] [Related]
24. Genomic Changes Associated with the Loss of Nocardia brasiliensis Virulence in Mice after 200 In Vitro Passages.
Gonzalez-Carrillo C; Millan-Sauceda C; Lozano-Garza HG; Ortiz-Lopez R; Elizondo-Gonzalez R; Welsh O; Ocampo-Candiani J; Vera-Cabrera L
Infect Immun; 2016 Sep; 84(9):2595-606. PubMed ID: 27354446
[TBL] [Abstract][Full Text] [Related]
25. Humoral immunity through immunoglobulin M protects mice from an experimental actinomycetoma infection by Nocardia brasiliensis.
Salinas-Carmona MC; Pérez-Rivera I
Infect Immun; 2004 Oct; 72(10):5597-604. PubMed ID: 15385456
[TBL] [Abstract][Full Text] [Related]
26. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
27. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B
Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687
[TBL] [Abstract][Full Text] [Related]
28. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Ulrich M; Berger J; Möller JG; Döring G
Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
[TBL] [Abstract][Full Text] [Related]
29. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
30. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii.
Spence RP; Towner KJ
J Antimicrob Chemother; 2003 Oct; 52(4):687-90. PubMed ID: 12951327
[TBL] [Abstract][Full Text] [Related]
31. Actinomycetoma caused by Nocardia brasiliensis.
Motta RL; Vilela RV; Lambertucci JR
Rev Soc Bras Med Trop; 2004; 37(3):287-8. PubMed ID: 15330073
[No Abstract] [Full Text] [Related]
32. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
33. Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model.
Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():44-9. PubMed ID: 16518711
[TBL] [Abstract][Full Text] [Related]
34. Actinomycetoma and advances in its treatment.
Welsh O; Vera-Cabrera L; Welsh E; Salinas MC
Clin Dermatol; 2012; 30(4):372-81. PubMed ID: 22682184
[TBL] [Abstract][Full Text] [Related]
35. Retnla down-regulation and IL-13-rich environment correlate with inflammation severity in experimental actinomycetoma by Nocardia brasiliensis.
Meester I; Rosas-Taraco AG; Salinas-Carmona MC
Pathog Dis; 2013 Apr; 67(3):214-20. PubMed ID: 23620185
[TBL] [Abstract][Full Text] [Related]
36. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
37. Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Steward J; Piercy T; Lever MS; Nelson M; Simpson AJ; Brooks TJ
J Antimicrob Chemother; 2005 Apr; 55(4):523-7. PubMed ID: 15731198
[TBL] [Abstract][Full Text] [Related]
38. Nocardia brasiliensis: from microbe to human and experimental infections.
Salinas-Carmona MC
Microbes Infect; 2000 Sep; 2(11):1373-81. PubMed ID: 11018454
[TBL] [Abstract][Full Text] [Related]
39. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ
Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457
[TBL] [Abstract][Full Text] [Related]
40. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
